Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivo Abraham

Showing results (1-10 of 224) with videos related to

Pageof 23
Sort By:
International Urology and Nephrology|July 31, 2015
State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologistsAdrian Covic, Ivo Abraham
Expert Opinion on Biological Therapy|August 14, 2023
The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countriesMatthias Calamia, Ivo Abraham
Transfusion|February 9, 2012
The cost of blood transfusion in Western Europe as estimated from six studiesIvo Abraham, Diana Sun
Expert Opinion on Drug Safety|August 14, 2012
Clinical safety of biosimilar recombinant human erythropoietinsIvo Abraham, Karen MacDonald
International Journal of Nursing Studies|January 17, 2016
Psychometric comparison of single-item, short, and comprehensive depression screening measures in Korean young adultsHee-Ju Kim, Ivo Abraham
Clinical Nursing Research|September 22, 2020
Determinants of the Higher Prevalence and Severity of Subjective Cognitive Impairment in Cancer Patients Compared to Healthy Subjects: Fatigue and StressHee-Ju Kim, Ivo Abraham
International Journal of Nursing Studies|November 9, 2016
Measurement of fatigue: Comparison of the reliability and validity of single-item and short measures to a comprehensive measureHee-Ju Kim, Ivo Abraham
Journal of Medical Economics|July 17, 2024
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancerKaren MacDonald, Marc Pondel, Ivo Abraham
Journal of Medical Economics|March 15, 2024
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinomaKaren MacDonald, Marc Pondel, Ivo Abraham
Journal of Medical Economics|December 6, 2021
Economic evaluation of polatuzumab-bendamustine-rituximab <i>vs.</i> tafasitamab-lenalidomide in transplant-ineligible R/R DLBCLMatthias Calamia, Ali McBride, Ivo Abraham
Pageof 23

Showing results (1-10 of 224) with videos related to

Sort By:
Pageof 23
International Urology and Nephrology|July 31, 2015
State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologistsAdrian Covic, Ivo Abraham
Expert Opinion on Biological Therapy|August 14, 2023
The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countriesMatthias Calamia, Ivo Abraham
Transfusion|February 9, 2012
The cost of blood transfusion in Western Europe as estimated from six studiesIvo Abraham, Diana Sun
Expert Opinion on Drug Safety|August 14, 2012
Clinical safety of biosimilar recombinant human erythropoietinsIvo Abraham, Karen MacDonald
International Journal of Nursing Studies|January 17, 2016
Psychometric comparison of single-item, short, and comprehensive depression screening measures in Korean young adultsHee-Ju Kim, Ivo Abraham
Clinical Nursing Research|September 22, 2020
Determinants of the Higher Prevalence and Severity of Subjective Cognitive Impairment in Cancer Patients Compared to Healthy Subjects: Fatigue and StressHee-Ju Kim, Ivo Abraham
International Journal of Nursing Studies|November 9, 2016
Measurement of fatigue: Comparison of the reliability and validity of single-item and short measures to a comprehensive measureHee-Ju Kim, Ivo Abraham
Journal of Medical Economics|July 17, 2024
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancerKaren MacDonald, Marc Pondel, Ivo Abraham
Journal of Medical Economics|March 15, 2024
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinomaKaren MacDonald, Marc Pondel, Ivo Abraham
Journal of Medical Economics|December 6, 2021
Economic evaluation of polatuzumab-bendamustine-rituximab <i>vs.</i> tafasitamab-lenalidomide in transplant-ineligible R/R DLBCLMatthias Calamia, Ali McBride, Ivo Abraham
Pageof 23